ONCAlert | 2018 ASCO Annual Meeting

Dr. Thomas Herzog on Who Benefits From Neoadjuvant Therapies

Thomas Herzog, MD
Published Online: 5:50 PM, Fri November 6, 2015


Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.


Herzog says, in most cases, depending on the patient’s health, primary cytoreduction would be the ideal way to go for treatment. While he considers neoadjuvant therapies to be a standard of care, he does not consider them to be the standard of care.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.